AI-Designed GLP-1 Peptides Outperform Semaglutide

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) has announced promising results from in vitro studies of its AI-desi gned GLP-1 receptor agonist peptides. The data reveals that the company’s peptide candidates demonstrate equal or greater receptor activation compared to Semaglutide—a leading GLP-1 therapy and blockbuster drug in the diabetes and obesity space.

The thir

d-party-verified results reinforce the capabilities of IPA’s proprietary LENSai™ platform and HYFT™ technology. These platforms enable rational peptide design based on first-principles computational modeling and biological pattern recognition. Among five engineered peptides tested, two lead candidates surpassed or matched Semaglutide in receptor activation assays under controlled lab conditions.

Unlike traditional methods, the IPA peptides were not found by trial-and-error but through mathematically derived biological models generated via HYFT™. This strategic approach enhances reproducibility and scalability across various therapeutic categories.

“These results represent more than just a scientific milestone,” said Dr. Jennifer Bath, CEO of ImmunoPrecise. “They prove that our HYFT™-guided AI design process can repeatedly deliver potent and biologically relevant peptide therapeutics. This signals a transformative shift in how new drugs are discovered.”

With the GLP-1 drug market growing rapidly, IPA plans to move forward with two preclinical development paths for its leading candidates: injecta

ble delivery assessments, including pharmacokinetics and animal model testing, and exploration of non-invasive approaches like transdermal patches and nucleic acid-based delivery systems aimed at enhancing patient compliance.

Additionally, the peptides are engineered to integrate with next-generation expression systems, inc

luding nucleic acid vectors, ensuring scalable development in human-relevant platforms. This positions the candidates for faster regulatory and commercial align ment.

IPA’s success with GLP-1 peptides follows recent breakthroughs in AI-designed dengue vaccine candidates, highli ghting the broad applicability of its platform for both infectious and non-infectious diseases. The company, which collaborates with 19 of the top 20 global pharmaceutical firms, continues to advance its mission of revolutionizing biotherapeut

ics through AI-led innov ation.

Explore More Cutting-Edge Tech Like This – Stay ahead of the game. Visit IT Tech News for more insights on AI, data tech, and innovation shaping our future.

News Source: Businesswire.com